Potential conflict of interest: Dr. O'Brien is an inventor on patent applications filed by the National Cancer Institute for the IFNL4-ΔG (ss469415590) genotype-based test and for the IFNL4 protein. Dr. Morgan received grants from Bristol-Myers Squibb, Genentech, Gilead, Vertex, and Merck.
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
Article first published online: 14 APR 2014
© 2014 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Volume 59, Issue 6, pages 2423–2424, June 2014
How to Cite
Wang, A. S., Pfeiffer, R. M., Morgan, T. R. and O'Brien, T. R. (2014), Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology, 59: 2423–2424. doi: 10.1002/hep.26771
- Issue published online: 28 MAY 2014
- Article first published online: 14 APR 2014
- Accepted manuscript online: 7 OCT 2013 04:15PM EST
- Manuscript Accepted: 29 AUG 2013
- Manuscript Received: 7 AUG 2013